(Print or Tyne Responses)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

T THE OT T I SO TEAD OHIOSO
Drapé Eric	1. Name and Address of Reporting Person		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title below) Other (specify below)
(Last) 124 Dvora HaNevi'a St.,	(First) (Middle) C/O Teva Pharmaceutical Industries Ltd.		3. Date of Earliest Transaction (Month/Day/Year) 02/16/2024	Executive VP Global Operations
(Street) Tel Aviv, L3 6944020			4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)

1.Title of Security	12. Transaction	2A. Deemed		3. Transaction 4. Securities Acquired (A)			5. Amount of Securities		7. Nature
(Instr. 3)	Date	Execution Date, if Code					or Disposed of (D)		Beneficially Owned Following	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)	(Instr. 3, 4 and 5)			Reported Transaction(s)	i Form:	Beneficial
		(Month/Day/Year)					(Instr. 3 and 4)		Direct (D) Ownership
					(A)			or Indirect (Instr. 4)
					Or			(1)
			Code	Amount	(D)	Price		(Instr. 4)

Ordinary Shares (1)	02/16/2024							1 (3) =
---------------------	------------	--	--	--	--	--	--	---------	--	--

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

( e.g. , puts, calls, warrants, options, convertible securities)
------------------------------------------------------------------	--	--

1. Title of		3. Transaction	3A. Deemed	4.	5. Number		16. Date Exercisable		7. Title and			8. Price of 9. Number of	10	11. Nature
Derivative	Conversion Date		Execution Date, if Transaction		of		and Expiration Date			Amount of		Derivative Derivative	Ownership of Indirect
Security		or Exercise (Month/Day/Year) any		Code				Underlying Derivative (Month/Day/Year)			Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year) (Instr. 8)		Securities					Securities	(Instr. 5)	Beneficially		Derivative Ownership
	Derivative				Acquired					(Instr. 3 and 4)		owned	Security:	(Instr. 4)
	Security				(A) or							Following	Direct (D)
					Disposed							Reported	or Indirect
					lof (D)							Transaction(s) (I)
					(Instr. 3, 4,							(Instr. 4)	(Instr. 4)
					and 5)
										Amount



				Code	(A)	(D)	Date Exercisable Date	Expiration	Title	Or Number of Shares

Explanation of Responses:

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
1. The price reported in Column 4 is a weighted avers only in multiple transactions at proces ranging from \$ 1.0 to \$ 1.1. includive. The reportuge, person underchast to provide, upon request by the SEC statify holder of the issuer, full information regarding the number of shares sold at each separate price.
1. Number of shares rounded to the nearest whole share.

/s/ Dov Bergwerk as attorney-in-fact for Eric Drape 02/21/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.